El-Khoueiry, MD, associate professor of clinical medicine and phase 1 program director at the University of South California Norris Comprehensive Cancer Center, said during a press conference. “
For patients with advanced disease, who are the majority of
patients we see, sorafenib (Nexavar; Bayer, Onyx) is the only FDA-approved systemic treatment, with an average survival of less than 11 months. After failure of sorafenib, there is no current standard of care.